Justin Zelin Analyst PerformanceDirector, Biotechnology Equity Research Analyst at BTIG ResearchJustin Zelin is a stock analyst at BTIG Research focused in the medical sector, covering 15 publicly traded companies. Over the past year, Justin Zelin has issued 22 stock ratings, including strong buy, buy, and hold recommendations. While full access to Justin Zelin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Justin Zelin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings28 Last 4 YearsBuy Recommendations92.86% 26 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution28RatingsDistribution of strong buy, buy, hold, and sell ratings by Justin Zelin.RatingPercentageCount Strong Buy3.6%1 ratings Buy89.3%25 ratings Hold7.1%2 ratings Sell0.0%0 ratingsOut of 28 total stock ratings issued by Justin Zelin at BTIG Research, the majority (89.3%) have been Buy recommendations, followed by 7.1% Hold and 3.6% Strong Buy.Best & Worst CallsBest Call0000.0%BLUSep 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%MBIOJun 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ93.3% of companies on NASDAQ14 companiesTSE6.7% of companies on TSE1 companyJustin Zelin, an analyst at BTIG Research, currently covers 15 companies listed on NASDAQ and TSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical14 companies93.3%Finance1 company6.7%Justin Zelin of BTIG Research specializes in stock coverage within the Medical sector, with additional focus on Finance companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies86.7%FIN - MISC SVCS1 company6.7%BIOTECHNOLOGY1 company6.7% About Justin ZelinJustin Zelin is a Director and BTIG Biotechnology Analyst, specializing in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics. Prior to BTIG, Mr. Zelin was a Biotech Equity Research Analyst at B. Riley Securities. Previously, he held biotech equity research associate roles at Canaccord Genuity and SVB Leerink. Earlier in his career, Mr. Zelin worked in both academic and industry labs including Agenus, Harvard University and Brigham and Women’s Hospital. He was also a member of Harvard University’s teaching staff for more than five years. Mr. Zelin earned a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University.Follow on LinkedIn Justin Zelin's Ratings History at BTIG Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsVKTXViking Therapeutics2/26/2026Upgrade$33.84Strong-Buy$0.0000.00% ROIIBRXImmunityBio1/22/2026Boost Price Target$7.34$9.00Buy$0.0000.00% ROIAVBPArriVent BioPharma12/10/2025Initiated Coverage$24.91$45.00Buy$0.0000.00% ROIAVBPArriVent BioPharma12/10/2025Initiated Coverage$24.35$45.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals12/9/2025Reiterated Rating$19.98$56.00Buy$0.0000.00% ROICANCanaan12/8/2025Initiated Coverage$0.93$3.00Buy$0.0000.00% ROIMRSNMersana Therapeutics11/13/2025Downgrade$27.53Hold$0.0000.00% ROIAAPGAscentage Pharma Group International11/10/2025Initiated Coverage$31.73$50.00Buy$0.0000.00% ROITCRXTScan Therapeutics11/4/2025Downgrade$1.24Neutral$0.0000.00% ROIIPHAInnate Pharma10/29/2025Reiterated Rating$2.10$8.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals10/27/2025Reiterated Rating$13.53$56.00Buy$0.0000.00% ROIIMABI-Mab10/24/2025Reiterated Rating$4.39$9.00Buy$0.0000.00% ROIIDYAIDEAYA Biosciences10/21/2025Reiterated Rating$30.51$62.00Buy$0.0000.00% ROIIMABI-Mab10/17/2025Boost Price Target$5.85$9.00Buy$0.0000.00% ROICANCanaan10/14/2025Reiterated Rating$1.52$8.00Buy$0.0000.00% ROIJSPRJasper Therapeutics9/22/2025Lower Price Target$2.50$7.00Buy$0.0000.00% ROIVKTXViking Therapeutics9/22/2025Reiterated Rating$26.58$125.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals9/19/2025Reiterated Rating$14.77$56.00Buy$0.0000.00% ROIIMABI-Mab9/9/2025Initiated Coverage$4.27$7.00Buy$0.0000.00% ROIVSTMVerastem9/9/2025Reiterated Rating$10.23$20.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals8/5/2025Boost Price Target$12.23$56.00Buy$0.0000.00% ROIJSPRJasper Therapeutics7/7/2025Lower Price Target$3.04$20.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
